A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India
Introduction: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven an...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-08-01
|
| Series: | Complementary Therapies in Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0965229922000267 |
| _version_ | 1818006573639794688 |
|---|---|
| author | Ajay Prabhakar Sankhe Nanasaheb Somnath Memane Vijaykumar P. Gawali Sonal Nanasaheb Memane Ganesh Ramakrishnan Tapanendu Kundu Mayur Nimba Bagul Ashotosh Kumar Vikram Bansal Rashmi Tiwari |
| author_facet | Ajay Prabhakar Sankhe Nanasaheb Somnath Memane Vijaykumar P. Gawali Sonal Nanasaheb Memane Ganesh Ramakrishnan Tapanendu Kundu Mayur Nimba Bagul Ashotosh Kumar Vikram Bansal Rashmi Tiwari |
| author_sort | Ajay Prabhakar Sankhe |
| collection | DOAJ |
| description | Introduction: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven antiviral, detoxifying, immune-modulating, and bio-enhancing properties. The present study was carried out to evaluate the therapeutic effect and safety of Ayurcov in patients with various severity states of COVID-19 infections. Methods: A randomized, single blinded, controlled trial was carried out in adults diagnosed with mild-to-moderate, and severe COVID-19 infections confirmed by real time reverse transcriptase polymerase chain reaction (rRTPCR) test. The interventional group received three doses of ‘Ayurcov’. It is constituted of Haridra Churna (Curcuma longa), Go ark (Bos Indicus Distilled Urine), Sphatika (Alum), Sita (Rock Candy), Godugdham (Bos Indicus Milk) milk, Goghritam (Bos Indicus ghee) on Day 1, as an adjuvant to the standard of care, and the control group received only the standard of care. Key outcomes included: proportion of patients and time taken for symptom resolution, reduction in the rRT-PCR Ct values, safety, and functional status until 42 days after discharge. Results: Ninety patients with mild-to-moderate and 30 patients with severe COVID-19 disease were recruited. It was observed that significantly more proportions of patients receiving Ayurcov had symptom relief much earlier than control group. Additionally, the interventional group showed significantly lower rRT-PCR Ct values. However, a shorter time of resolution of symptoms was observed with the interventional group in the mild to moderate category but not with those having severe symptoms. Similarly, a significantly better functional status was observed with interventional group on days 7 and 28 after discharge. Ayurcov was not observed with higher risks of any adverse/serious adverse events. Conclusions: Ayurcov as adjuvant with standard of care was associated with significantly earlier resolution of COVID-19 related symptoms than standard of care alone. |
| first_indexed | 2024-04-14T05:03:51Z |
| format | Article |
| id | doaj.art-995365d6f503438ea1fac645b591a8f1 |
| institution | Directory Open Access Journal |
| issn | 0965-2299 |
| language | English |
| last_indexed | 2024-04-14T05:03:51Z |
| publishDate | 2022-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Complementary Therapies in Medicine |
| spelling | doaj.art-995365d6f503438ea1fac645b591a8f12022-12-22T02:10:50ZengElsevierComplementary Therapies in Medicine0965-22992022-08-0167102824A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in IndiaAjay Prabhakar Sankhe0Nanasaheb Somnath Memane1Vijaykumar P. Gawali2Sonal Nanasaheb Memane3Ganesh Ramakrishnan4Tapanendu Kundu5Mayur Nimba Bagul6Ashotosh Kumar7Vikram Bansal8Rashmi Tiwari9Bhaktivedanta Hospital and Research Institute, India; Correspondence to: Bhaktivedanta Hospital and Research Institute, Mira Road, Thane, Maharashtra, India.Bhaktivedanta Hospital and Research Institute, IndiaBhaktivedanta Hospital and Research Institute, IndiaBhaktivedanta Hospital and Research Institute, IndiaIndian Institute of Technology, Bombay, IndiaIndian Institute of Technology, Bombay, IndiaBhaktivedanta Hospital and Research Institute, IndiaIndian Institute of Technology, Bombay, IndiaIndian Institute of Technology, Bombay, IndiaIndian Institute of Technology, Bombay, IndiaIntroduction: Limited treatment options exist for COVID-19 infections; thus, attempts from complementary and alternative systems (CAM) of medicine are being explored as possible therapeutic options. Ayurcov is a formulation made of ingredients mentioned in Ayurveda. These constituents have proven antiviral, detoxifying, immune-modulating, and bio-enhancing properties. The present study was carried out to evaluate the therapeutic effect and safety of Ayurcov in patients with various severity states of COVID-19 infections. Methods: A randomized, single blinded, controlled trial was carried out in adults diagnosed with mild-to-moderate, and severe COVID-19 infections confirmed by real time reverse transcriptase polymerase chain reaction (rRTPCR) test. The interventional group received three doses of ‘Ayurcov’. It is constituted of Haridra Churna (Curcuma longa), Go ark (Bos Indicus Distilled Urine), Sphatika (Alum), Sita (Rock Candy), Godugdham (Bos Indicus Milk) milk, Goghritam (Bos Indicus ghee) on Day 1, as an adjuvant to the standard of care, and the control group received only the standard of care. Key outcomes included: proportion of patients and time taken for symptom resolution, reduction in the rRT-PCR Ct values, safety, and functional status until 42 days after discharge. Results: Ninety patients with mild-to-moderate and 30 patients with severe COVID-19 disease were recruited. It was observed that significantly more proportions of patients receiving Ayurcov had symptom relief much earlier than control group. Additionally, the interventional group showed significantly lower rRT-PCR Ct values. However, a shorter time of resolution of symptoms was observed with the interventional group in the mild to moderate category but not with those having severe symptoms. Similarly, a significantly better functional status was observed with interventional group on days 7 and 28 after discharge. Ayurcov was not observed with higher risks of any adverse/serious adverse events. Conclusions: Ayurcov as adjuvant with standard of care was associated with significantly earlier resolution of COVID-19 related symptoms than standard of care alone.http://www.sciencedirect.com/science/article/pii/S0965229922000267COVID-19AyurvedaCAMComplementary and alternative medicineAyurcov |
| spellingShingle | Ajay Prabhakar Sankhe Nanasaheb Somnath Memane Vijaykumar P. Gawali Sonal Nanasaheb Memane Ganesh Ramakrishnan Tapanendu Kundu Mayur Nimba Bagul Ashotosh Kumar Vikram Bansal Rashmi Tiwari A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India Complementary Therapies in Medicine COVID-19 Ayurveda CAM Complementary and alternative medicine Ayurcov |
| title | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
| title_full | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
| title_fullStr | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
| title_full_unstemmed | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
| title_short | A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India |
| title_sort | randomized controlled blinded parallel group clinical trial to study the role of ayurcov ayurcoro3 one day regimen as an adjuvant therapy for covid 19 disease management at dedicated covid hospital dch in india |
| topic | COVID-19 Ayurveda CAM Complementary and alternative medicine Ayurcov |
| url | http://www.sciencedirect.com/science/article/pii/S0965229922000267 |
| work_keys_str_mv | AT ajayprabhakarsankhe arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT nanasahebsomnathmemane arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT vijaykumarpgawali arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT sonalnanasahebmemane arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT ganeshramakrishnan arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT tapanendukundu arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT mayurnimbabagul arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT ashotoshkumar arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT vikrambansal arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT rashmitiwari arandomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT ajayprabhakarsankhe randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT nanasahebsomnathmemane randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT vijaykumarpgawali randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT sonalnanasahebmemane randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT ganeshramakrishnan randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT tapanendukundu randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT mayurnimbabagul randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT ashotoshkumar randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT vikrambansal randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia AT rashmitiwari randomizedcontrolledblindedparallelgroupclinicaltrialtostudytheroleofayurcovayurcoro3onedayregimenasanadjuvanttherapyforcovid19diseasemanagementatdedicatedcovidhospitaldchinindia |